Your cart is empty.
Developing drugs that are effective, with minimal side effects, is important to improve the lives of patients suffering from serious diseases. Leading biotechnology company Amgen focuses on producing therapies for a wide range of conditions, and is currently developing small interfering RNAs (siRNAs) as a method to treat patients with a genetic predisposition to heart disease.
Mass spectrometry is now routinely used for clinical diagnostics around the world, but manual sample preparation and traditional liquid-liquid extraction techniques are very time consuming, requiring new approaches to help streamline laboratory workflows. The endocrinology service at Charing Cross Hospital is using high throughput automated SPE to accelerate mass spec sample prep, improving turnaround times and freeing up staff time to develop new assays.